Labetalol
Alpha and Beta Blocking Agents
- Drug class
- Alpha and Beta Blocking Agents
- Availability
- Prescription only
- Routes
- Intravenous, Oral
- Markets covered
- 3
- Products on record
- 27
- FDA reports (12 mo)
- 667
Overview
Labetalol is an active pharmaceutical ingredient in the Alpha and Beta Blocking Agents group (C07AG). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 13 | May 15, 2026 |
| CA Canada | Health Canada | 8 | July 15, 2025 |
| US United States | FDA | 6 | May 22, 2026 |
GBUnited Kingdom· MHRA
13 products
Uses
Labetalol Tablets are indicated for the treatment of: • Mild, moderate and severe hypertension • Hypertension in pregnancy • Angina pectoris with existing hypertension
How to take
CACanada· Health Canada
8 products
Uses
AND CLINICAL USE ........................................................................ 3 CONTRAINDICATIONS ............................................................................................ 3 WARNINGS AND PRECAUTIONS............................................................................
4 ADVERSE REACTIONS............................................................................................. 7 DRUG INTERACTIONS ............................................................................................. 15 PART II: SCIENTIFIC INFORMATION ..........................................................................
22 PART III: PATIENT MEDICATION INFORMATION.................................................... 25 Labetalol Hydrochloride Injection USP Page 3 of 29 PrLABETALOL HYDROCHLORIDE INJECTION USP Labetalol hydrochloride PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Administration Dosage Form / Strength Nonmedicinal Ingredients Intravenous Solution for injection 5 mg / mL Dextrose anhydrous, disodium edetate, methylparaben (preservative), propylparaben (preservative), anhydrous citric acid and/or sodium hydroxide to adjust pH, and water for injection.
USUnited States· FDA
6 products
Uses
INDICATIONS AND USAGE
Labetalol hydrochloride tablets USP are indicated in the management of hypertension. Labetalol hydrochloride tablets USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics.
How to take
Drug interactions
Known interactions involving Labetalol. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 527. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL113110376 · revised November 22, 2024
- [2]Health Canada (DPD) · 02231689 · revised March 22, 2025
- [3]FDA DailyMed · 04f9dcdf-4023-48… · revised May 22, 2026 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.